Intronbio's iN-SIS5: Pharmacological Applications and Patent on Manufacturing Methods

Intronbio's new drug division announced on the 25th that it has recently registered an additional patent for the pharmaceutical use of iN-SIS5, a cosmetic material developed as a Botox alternative.

The patent technology for the substance and use related to the cosmetic application of iN-SIS5 has already been registered, and this time, a use patent technology for medical and pharmaceutical applications has also been registered. The company explained that iN-SIS5 has secured foundational patents that allow its use not only for cosmetic purposes but also for medical purposes. In addition to substance and use patents, patent technology for the manufacturing method of iN-SIS5 has also been secured.

In the Botox (BoNT)-related market, BoNT-like materials such as BoNT variants or peptides introduced as having similar functions are being applied, but there are still limitations in their effectiveness. iN-SIS5 provides effects similar to BoNT while overcoming BoNT's drawbacks. Furthermore, it can be considered a new BoNT alternative material that offers differentiated advantages.

Kang Sang-hyun, Vice President of Intronbio, said, "iN-SIS5 is expected to be a drug used not only in the cosmetic field but also in medical fields such as hyperhidrosis," adding, "We have secured patent rights for all aspects related to iN-SIS5."

Yoon Kyung-won, CEO of Intronbio, explained, "We are considering various business initiatives by effectively utilizing the strengthened patent rights," and added, "Currently, we are focusing on the use of iN-SIS5 in the cosmetic field." He further stated, "We plan to promote the use of iN-SIS5 in various business sectors."

This content was produced with the assistance of AI translation services.